Zevra Therapeutics, Inc. (ZVRA)
12.01
-0.05
(-0.41%)
USD |
NASDAQ |
Sep 11, 16:00
11.77
-0.24
(-2.00%)
After-Hours: 05:28
Zevra Therapeutics Enterprise Value : 492.62M for Sept. 11, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| September 11, 2026 | 492.62M |
| September 10, 2026 | 495.59M |
| September 09, 2026 | 494.40M |
| September 08, 2026 | 532.08M |
| September 04, 2026 | 515.77M |
| September 03, 2026 | 524.07M |
| September 02, 2026 | 509.83M |
| September 01, 2026 | 495.59M |
| August 31, 2026 | 476.60M |
| August 28, 2026 | 466.22M |
| August 27, 2026 | 483.13M |
| August 26, 2026 | 476.60M |
| August 25, 2026 | 494.40M |
| August 24, 2026 | 471.26M |
| August 21, 2026 | 484.31M |
| August 20, 2026 | 485.50M |
| August 19, 2026 | 499.74M |
| August 18, 2026 | 466.51M |
| August 17, 2026 | 464.14M |
| August 14, 2026 | 451.68M |
| August 13, 2026 | 443.37M |
| August 12, 2026 | 458.80M |
| August 11, 2026 | 452.86M |
| August 10, 2026 | 461.17M |
| August 07, 2026 | 465.92M |
| Date | Value |
|---|---|
| August 06, 2026 | 484.91M |
| August 05, 2026 | 404.80M |
| August 04, 2026 | 404.20M |
| August 03, 2026 | 376.61M |
| July 31, 2026 | 344.27M |
| July 30, 2026 | 351.98M |
| July 29, 2026 | 360.29M |
| July 28, 2026 | 357.32M |
| July 27, 2026 | 356.14M |
| July 24, 2026 | 345.16M |
| July 23, 2026 | 522.89M |
| July 22, 2026 | 500.34M |
| July 21, 2026 | 518.73M |
| July 20, 2026 | 493.81M |
| July 17, 2026 | 537.72M |
| July 16, 2026 | 537.13M |
| July 15, 2026 | 549.00M |
| July 14, 2026 | 554.93M |
| July 13, 2026 | 562.05M |
| July 10, 2026 | 572.14M |
| July 09, 2026 | 607.15M |
| July 08, 2026 | 655.22M |
| July 07, 2026 | 636.82M |
| July 06, 2026 | 608.93M |
| July 02, 2026 | 609.53M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Innoviva, Inc. | 1.191B |
| Collegium Pharmaceutical, Inc. | 1.808B |
| Johnson & Johnson | 667.86B |
| Ligand Pharmaceuticals, Inc. | 5.440B |
| Harrow, Inc. | 1.509B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 8.393M |
| Revenue (Quarterly) | 39.66M |
| Total Expenses (Quarterly) | 31.27M |
| EPS Diluted (Quarterly) | 0.1368 |
| Gross Profit Margin (Quarterly) | 95.36% |
| Profit Margin (Quarterly) | 21.16% |
| Earnings Yield | 7.72% |
| Operating Earnings Yield | 5.48% |
| Normalized Earnings Yield | 9.446 |